AC Immune’s antibody shows therapeutic effect in Alzheimer’s patients

AC Immune’s antibody shows therapeutic effect in Alzheimer’s patients

31.8.2021 – Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate Alzheimer’s Disease shows a statistically significant reduction in cognitive decline. Following the announcement of the results, AC Immune’s share price increased significantly.

Read more in startupticker